Kimberly Gentile

Ms. Gentile has 30 years of experience in the pharmaceutical industry in all phases of clinical research from Phase 1 through Phase 4, predominantly in the areas of psychiatry and neurology. She has deep, hands-on experience in most key operational aspects of drug development, having held positions at small biotechnology companies, contract research organizations, investigative sites as well as small and large pharmaceutical companies. Prior to joining Biohaven in 2014, Ms. Gentile spent 14 years in the Clinical Operations group at Bristol-Myers Squibb where she was responsible for operational oversight of large-scale global programs in the areas of psychiatry and neurology, including the management of complex global programs in Anxiety Disorders, Treatment Resistant Depression and Alzheimer’s Disease. She has a proven track record of successfully managing complex and challenging drug development programs within set timelines and budgets.